The Biochemistry, Biology and Pathology of MAP Kinases II

The Biochemistry, Biology and Pathology of MAP Kinases II The Biochemistry, Biology and Pathology of MAP Kinases II. 10-11 September, 2014 in Vilnius Lithuania. Organizing committee:
Dr. Jonas Cicenas - chairman
Prof.

The Biochemistry, Biology and Pathology of MAP Kinases II. 10-11 Septermber, 2014 in Vilnius Lithuania. FORMAT:
Conference
Company visits
Poster session
Social program

Organizers:
MAP Kinase Resource , Enterprise Lithuania, Life Sciences Baltics, Lithuanian Biotechnology Association. Rony Seger
Dr. Mindaugas Valius
Prof. Jean-François Bodart

Keynote speakers:

Gary L. Johnson, University of North Carolina School of Medicine, Chapel Hill, NC, USA

Rony Seger, The Weizmann Institute of Science, Rehovot, Israel


Other invited speakers :

Anna Czarnecka, Military Institute of Medicine, Warsaw, Poland

Antigone Lazou, Aristotle University of Thessaloniki Thessaloniki, Greece

Audrone Kalvelyte, Vilnius University Institute of Biochemistry, Vilnius, Lithuania

Cristophe Bonny, University of Lausanne, Lausanne, Switzerland

Daiva Bironaite, State Research Institute Centre for Innovative Medicine, Vilnius, Lithuania

David Engelberg, The Hebrew University of Jerusalem, Jerusalem, Israel

Franziska Witzel, Charite, Berlin, Germany

Irute Meskiene, University of Vienna, Vienna, Austria

Jean-Francois Bodart, Université des Sciences et Technologies de Lille, Villeneuve d'Ascq, France

Jokubas Ziburkus, University of Houston, Houston, USA

Jonas Cicenas, Swiss Institute of Bioinformatics and MAP Kinase Resource, Geneva, Switzerland

Kanaga Sabapathy, National Cancer Center, Singapore, Singapore

Karthik Kalyan, Haffkine Institute, Mumbai, India

Lee M. Graves, The University of North Carolina, Chapel Hill, USA

Li Xing, Pfizer, Cambridge, USA

Matthias Gaestel, Hannover Medical University, Hannover, Germany

Mindaugas Valius, Proteomics Center, Vilnius, Lithuania

Pascale Gaudet, Swiss Institute of Bioinformatics, Geneva, Switzerland

Romeo Ricci, University of Strasbourg, Strasbourg, France

Simon Cook, The Babraham Institute, Cambridge, UK

Steven Pelech, Kinexus Bioinformatics Corporation, Vancouver, Canada

Tiziana Borsello, University Mario Negri, Milan, Italy

Due to the success of the first volume on “Kinases in Cancer and Other Diseases”, we are glad to announce that thesecond...
31/08/2023

Due to the success of the first volume on “Kinases in Cancer and Other Diseases”, we are glad to announce that the
second volume of this Topic is opening for submission now.
Topic: Kinases in Cancer and Other Diseases, 2nd Edition
Deadline for manuscript submissions: 31 December 2024
Particapting journals: Cells (SCI, IF 6.0); IJMS (SCI, IF 5.6); Biomolecules (SCI, IF 5.5); Cancers (SCI, IF 5.2);
Pharmaceuticals (SCI, IF 4.6); Biology (SCI, IF 4.2)
Website:

MDPI is a publisher of peer-reviewed, open access journals since its establishment in 1996.

https://www.mdpi.com/2072-6694/11/7/972/htm
11/07/2019

https://www.mdpi.com/2072-6694/11/7/972/htm

Antitumor drug resistance remains a major challenge in cancer chemotherapy. Here we investigated the mechanism of acquired resistance to a novel anticancer agent RH1 designed to be activated in cancer cells by the NQO1 enzyme. Data show that in some cancer cells RH1 may act in an NQO1-independent wa...

https://www.mdpi.com/2072-6694/11/1/17/htm
24/12/2018

https://www.mdpi.com/2072-6694/11/1/17/htm

Glioma is the most aggressive brain tumor of the central nervous system. The ability of glioma cells to migrate, rapidly diffuse and invade normal adjacent tissue, their sustained proliferation, and heterogeneity contribute to an overall survival of approximately 15 months for most patients with hig...

28/04/2017

http://www.mdpi.com/2072-6694/9/5/42 and http://www.mdpi.com/2072-6694/9/5/42/htm

Pancreatic cancer is a disease that has a very high fatality rate and one of the highest mortality ratios among all major cancers, remaining the fourth leading cause of cancer-related deaths in developed countries. The major treatment of pancreatic cancer is surgery; however, only 15–20% of patients...

http://link.springer.com/article/10.1007%2Fs12032-016-0758-4
03/04/2016

http://link.springer.com/article/10.1007%2Fs12032-016-0758-4

Inhibitors that impact function of kinases are valuable both for the biological research as well as therapy of kinase-associated diseases, such as different cancers. There are quite a number of inhibitors, which are quite specific for certain kinases and several of them are either already approved f…

http://link.springer.com/article/10.1007/s00432-016-2136-1
06/03/2016

http://link.springer.com/article/10.1007/s00432-016-2136-1

Compounds that affect enzymatic function of kinases are valuable for the understanding of the complex biochemical processes in cells. Aurora kinases (AURKs) play a key role in the control of the mitosis. These kinases are frequently deregulated in different human cancers: overexpression, amplificati…

Address

Vilnius

Alerts

Be the first to know and let us send you an email when The Biochemistry, Biology and Pathology of MAP Kinases II posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram